Several management guidelines for lupus nephritis have been published this year. All of the guidelines provide clear and consistent recommendations, but although evidence-based, many of the recommendations are not supported by high-quality clinical data. The guidelines reveal these evidence gaps and are thus an important roadmap for future lupus nephritis clinical research.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hahn, B. H. et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res. (Hoboken) 64, 797–808 (2012).
Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int. Suppl. 2, 139–274 (2012).
Bertsias, G. K. et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2012-201940.
Rovin, B. H. et al. Lupus nephritis: Induction therapy in severe lupus nephritis: should MMF be considered the drug of choice? Clin. J. Am. Soc. Nephrol. http://dx.doi.org/10.2215/CJN.03290412.
Appel, G. B. et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J. Am. Soc. Nephrol. 20, 1103–1112 (2009).
Zahr, N. et al. Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil. Arthritis Rheum. 62, 2047–2054 (2010).
Lertdumrongluk, P. et al. Pharmacokinetics of mycophenolic acid in severe lupus nephritis. Kidney Int. 78, 389–395 (2010).
Houssiau, F. A. et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose versus high-dose intravenous cyclophosphamide. Ann. Rheum. Dis. 69, 61–64 (2010).
US National Library of Medicine. ClinicalTrials.gov[online], (2012).
Rovin, B. H. Glomerular disease: Lupus nephritis treatment: are we beyond cyclophosphamide? Nat. Rev. Nephrol. 5, 492–494 (2009).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author has worked as a consultant for Biogen Idec, Lilly and Questcor, and received a research grant from Teva.
Rights and permissions
About this article
Cite this article
Rovin, B. Guidelines for lupus nephritis—more recommendations than data?. Nat Rev Nephrol 8, 620–621 (2012). https://doi.org/10.1038/nrneph.2012.215
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2012.215
This article is cited by
-
Mycophenolate mofetil for sustained remission in nephrotic syndrome
Pediatric Nephrology (2018)
-
Effect of mycophenolic acid in experimental, nontransplant glomerular diseases: new mechanisms beyond immune cells
Pediatric Nephrology (2017)
